Matthews GV - Search Results

1

Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.

Martinello M, Bhagani S, Gane E, Orkin C, Cooke G, Dore GJ, Petoumenos K, Applegate TL, Tu E, Marks P, Pagani N, Grebely J, Nelson M, Matthews GV. Martinello M, et al. Among authors: matthews gv. J Viral Hepat. 2018 Oct;25(10):1180-1188. doi: 10.1111/jvh.12917. Epub 2018 May 8. J Viral Hepat. 2018. PMID: 29660224 Clinical Trial.

2

Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy.

Matthews GV, Moyle GJ, Mandalia S, Bower M, Nelson M, Gazzard BG. Matthews GV, et al. J Acquir Immune Defic Syndr. 2000 Aug 1;24(4):310-5. doi: 10.1097/00126334-200008010-00002. J Acquir Immune Defic Syndr. 2000. PMID: 11015146

3

Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy.

Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Matthews GV, et al. Blood. 2000 Oct 15;96(8):2730-4. Blood. 2000. PMID: 11023505 Free article.

4

The management of chronic hepatitis B infection.

Matthews GV, Nelson MR. Matthews GV, et al. Int J STD AIDS. 2001 Jun;12(6):353-7. doi: 10.1258/0956462011923273. Int J STD AIDS. 2001. PMID: 11368814 Review.

5

Failure of combination therapy with lamivudine and famciclovir following lamivudine monotherapy for hepatitis B virus infection in patients coinfected with human immunodeficiency virus-1.

Matthews GV, Pillay D, Cane P, Ratcliffe D, Gazzard B, Nelson M. Matthews GV, et al. Clin Infect Dis. 2001 Dec 15;33(12):2049-54. doi: 10.1086/322655. Epub 2001 Nov 5. Clin Infect Dis. 2001. PMID: 11698987

6

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.

Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR, Bower M, Johnson MA, Gazzard BG. Matthews GV, et al. AIDS. 2002 Jan 4;16(1):53-61. doi: 10.1097/00002030-200201040-00008. AIDS. 2002. PMID: 11741163 Clinical Trial.

7

An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.

Nelson M, Portsmouth S, Stebbing J, Atkins M, Barr A, Matthews G, Pillay D, Fisher M, Bower M, Gazzard B. Nelson M, et al. AIDS. 2003 Jan 3;17(1):F7-10. doi: 10.1097/00002030-200301030-00002. AIDS. 2003. PMID: 12478090 Clinical Trial.

8

Non-nucleoside reverse transcriptase inhibitors--an overview.

Bell C, Matthews GV, Nelson MR. Bell C, et al. Among authors: matthews gv. Int J STD AIDS. 2003 Feb;14(2):71-7. doi: 10.1258/095646203321156827. Int J STD AIDS. 2003. PMID: 12662384 Review. No abstract available.

9

BHIVA guidelines: coinfection with HIV and chronic hepatitis C virus.

Nelson MR, Matthews G, Brook MG, Main J; British HIV Association. Nelson MR, et al. HIV Med. 2003 Oct;4 Suppl 1:52-62. doi: 10.1046/j.1468-1293.4.s1.2.x. HIV Med. 2003. PMID: 14511248 Free article. No abstract available.

10

Response to Soriano et al., 'Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis?'.

Matthews G, Dore G. Matthews G, et al. AIDS. 2003 Dec 5;17(18):2675-6. doi: 10.1097/01.aids.0000104338.15729.9a. AIDS. 2003. PMID: 14685063 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

248 results

Search Page